EUVIMEDEUVIMED entdecken
Crossref

Enhanced affinity for the IL-2 receptor β subunit potently increases antitumor efficacy of IL-2 across various tumor models by reshaping the tumor microenvironment

Ernesto Relova-Hernández, Ana Beatriz Díaz-Bravo iD, Rodrigo Pedroso, Miguel Ángel Gonzalez-Cruz, Tania Gómez, Eliany Arias, Dayana Pérez-Martínez, Rydell Álvarez-Arzola, Janet Avellanet, Lisandra Padrón, Addys González Palomo, Luis Graça und 3 weitere

The Journal of Immunology · 2025

DOI: 10.1093/jimmun/vkaf208 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Immunology, 2025. Verfasst von Ernesto Relova-Hernández und 14 weiteren Autor:innen. Beteiligte Einrichtung: Center of Molecular Immunology, Havana, Cuba. Hauptthemen laut MEDLINE: Interleukin-2, Tumor Microenvironment, Interleukin-2 Receptor beta Subunit, Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 53 Literaturangaben. Gefördert von: Innovative Immune Alliance, PHC Carlos J. Finlay, Georg Forster.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The main limitations of cancer treatment with high doses of recombinant interleukin 2 (IL-2) are high toxicity and the undesired expansion of regulatory T cells. The generation of IL-2 mutated variants (muteins) with changes in the affinity for different chains of the IL-2 receptor (IL-2R) allows selective stimulation of effector cells while overcoming its toxicity. As increasing the IL-2 affinity for the IL-2R beta chain leads to better antitumor effect, we generated a group of these muteins using phage display technology, in a previous work. Recombinant Fc-fusion proteins, including these variants, resulted in improved developability properties and better in vivo effect than variants containing the IL-2 (IL-2Fc). Here, we assessed one such improved mutein, named superbeta 834 (SB834Fc), and performed a comprehensive characterization of its properties. This mutein showed a stronger antitumor effect than IL-2Fc in 5 murine tumor models: 3LL-D122, B16F10, CT26, MC38, and 4T1 at very low doses. Different from other IL-2 variants, SB834Fc, as single therapy, shows antitumor effect in a therapeutic injection scheme. This antitumor effect was coincident with strong stimulation of effector T cells in the spleen and in the tumor microenvironment, far above that observed with IL-2Fc, despite maintaining the same level of Treg stimulation. Additionally, induction of proliferation was demonstrated in CD8+ T cells isolated from human healthy donors, highlighting its translational value. These results support the SB834Fc fusion protein as a suitable candidate to develop a new cancer immunotherapy based in IL-2.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Interleukin-2Tumor MicroenvironmentInterleukin-2 Receptor beta SubunitNeoplasmsAnimalsMiceHumansFemaleCell Line, TumorT-Lymphocytes, RegulatoryMice, Inbred C57BLMice, Inbred BALB CImmunotherapy

Stichwörter der Autor:innen

IL-2 muteinIL-2FcIL-2Rβeffector cellssuperagonist

Substanzen

Interleukin-2Interleukin-2 Receptor beta Subunit

Autor:innen und Institutionen

  • Center of Molecular Immunology, Havana, Cuba.
  • Gulbenkian Institute for Molecular Medicine, Lisbon, Portugal.
  • Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal.

ORCID-Profile: Ana Beatriz Díaz-Bravo, Tania Carmenate

Förderung

  • Innovative Immune Alliance
  • PHC Carlos J. Finlay
  • Georg Forster
  • Alexander von Humboldt Foundation
  • French Embassy in Havana

Zitieren

APA

Relova-Hernández, E., Díaz-Bravo, A. B., Pedroso, R., Gonzalez-Cruz, M. Á., Gómez, T., Arias, E., Pérez-Martínez, D., Álvarez-Arzola, R., Avellanet, J., Padrón, L., González Palomo, A., Graça, L., León, K., Rojas, G., & Carmenate, T. (2025). Enhanced affinity for the IL-2 receptor β subunit potently increases antitumor efficacy of IL-2 across various tumor models by reshaping the tumor microenvironment. The Journal of Immunology. https://doi.org/10.1093/jimmun/vkaf208

Vancouver

Relova-Hernández E, Díaz-Bravo AB, Pedroso R, Gonzalez-Cruz MÁ, Gómez T, Arias E, et al. Enhanced affinity for the IL-2 receptor β subunit potently increases antitumor efficacy of IL-2 across various tumor models by reshaping the tumor microenvironment. The Journal of Immunology. 2025. doi:10.1093/jimmun/vkaf208

BibTeX
@article{RelovaHernndez2025,
  author = {Relova-Hernández, Ernesto and Díaz-Bravo, Ana Beatriz and Pedroso, Rodrigo and Gonzalez-Cruz, Miguel Ángel and Gómez, Tania and Arias, Eliany and Pérez-Martínez, Dayana and Álvarez-Arzola, Rydell and Avellanet, Janet and Padrón, Lisandra and González Palomo, Addys and Graça, Luis and León, Kalet and Rojas, Gertrudis and Carmenate, Tania},
  title = {Enhanced affinity for the IL-2 receptor β subunit potently increases antitumor efficacy of IL-2 across various tumor models by reshaping the tumor microenvironment},
  journal = {The Journal of Immunology},
  year = {2025},
  doi = {10.1093/jimmun/vkaf208}
}
Kostenlos starten →